News

A study looked at hospital admissions of Medicare patients and saw a large percentage of recurrent Clostridioides difficile infections (rCDI) as the primary diagnosis.

No difference was observed in any of the outcomes and there was no impact on the duration of therapy.

GDC and DSENS were both seen to be safe and effective tools to optimize therapy in the study participants.

An effort to increase stewardship showed that 5-day and 10-day prescription stop dates for antibiotics did little to influence actual therapy length and outcomes.

A diagnostic analyzer was studied looking at 3 biomarkers to predict the level of COVID-19, and could potentially serve as a risk stratification tool.

An assessment from the Cleveland Clinic shows prescribing concordant to guidelines can exceed 60% in certain facilities.

Almost half of the participants in the study had an opportunity to improve their antibiotic regimen.

The pilot program was demonstrated to significantly reduce days of antibiotic therapy.

More than half of the pharmacist led interventions were accepted by providers during the intervention period.

A majority of the study participants experienced symptoms that interfered with activities of their daily life.

A large retrospective analysis of Medicare patients offers a glimpse of the incidence rates of this patient population and the burdens associated with it.

The IL-6 targeting monoclonal antibody is linked to improved inflammatory and hemodynamic markers in hospitalized patients.

Interventions implemented by pharmacists were more likely to be accepted by prescribers.

A meta-analysis suggest the 2 first-line C diff therapies provide similar outcomes, yet differ in recurrent infection risk.

Study finds communicating on Electronic Medical Record (EMR) led to follow-up with infectious disease providers.

In-hospital mortality and recurrent bacteremia occurred in 58% and 17% of patients with persistent VRE BSIs.

A concerted effort to increase flu vaccination during the COVID-19 pandemic resulted in more protection among a high-risk population, as well as educational opportunities for pharmacy students.

Rates of in-hospital mortality and days with bacteremia were similar between the two study cohorts.

The federal agency elongates the time from 5 days up to 1 month for thawed out doses of the Pfizer-BioNTech vaccine.

Kits created by companies like Cepheid and bioMérieux will aid in the testing and treatment of viral infections in the future.

Children who experienced MIS-C showed an elevation of certain adaptive immune responses that confer immunological memory.

Patients who received the therapy had half the rate of mortality at 28 days after treatment.

The European Union (EU) agrees to look at easing restrictions for travelers from outside the continent, depending on vaccine or country status.

Studies are in early stages, according to the scientists at Rensselaer Polytechnic Institute (RPI) leading them.

The nanofiber filter was able to remove 99.9% of the coronavirus aerosols, while cotton masks only removed 45%-73%.

The novel sensor system is able to detect the presence of a virus in just 1 second.

Patients who were most likely to suffer complications and received the therapy had a 60% reduced chance of hospitalization and death.

A Roche test can be used in individuals not showing signs of symptomatic disease.

A study shows countries with the highest income levels had greater vaccine protection against rotavirus gastroenteritis (RVGE).

A new CDC study demonstrates effectiveness in a population with high exposure to the virus.